RecruitingPhase 2NCT05909618

Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases

Studying Glioblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sheba Medical Center
Principal Investigator
Ronnie Shapira Frommer, Dr
Ronnie Shapira, MD Study Principal Investigator Ronnie.Shapira@sheba.health.gov.il
Intervention
Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO](drug)
Enrollment
33 enrolled
Eligibility
18 years · All sexes
Timeline
20232030

Study locations (1)

Collaborators

Prof. Ronit Satchi-Fainaro, Director, Cancer Biology Research Center, Tel Aviv University, Tel Aviv, Israel.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05909618 on ClinicalTrials.gov

Other trials for Glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Glioblastoma

← Back to all trials